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Knockout of NMDA-receptors from parvalbumin
interneurons sensitizes to schizophrenia-related deﬁcits induced
by MK-801
AM Bygrave1, S Masiulis1, E Nicholson2, M Berkemann1,3, C Barkus4, R Sprengel5, PJ Harrison6, DM Kullmann2,8, DM Bannerman1,8 and
D Kätzel1,2,7,8
It has been suggested that a functional deﬁcit in NMDA-receptors (NMDARs) on parvalbumin (PV)-positive interneurons (PV-
NMDARs) is central to the pathophysiology of schizophrenia. Supportive evidence come from examination of genetically modiﬁed
mice where the obligatory NMDAR-subunit GluN1 (also known as NR1) has been deleted from PV interneurons by Cre-mediated
knockout of the corresponding gene Grin1 (Grin1ΔPV mice). Notably, such PV-speciﬁc GluN1 ablation has been reported to blunt the
induction of hyperlocomotion (a surrogate for psychosis) by pharmacological NMDAR blockade with the non-competitive
antagonist MK-801. This suggests PV-NMDARs as the site of the psychosis-inducing action of MK-801. In contrast to this hypothesis,
we show here that Grin1ΔPV mice are not protected against the effects of MK-801, but are in fact sensitized to many of them.
Compared with control animals, Grin1ΔPV mice injected with MK-801 show increased stereotypy and pronounced catalepsy, which
confound the locomotor readout. Furthermore, in Grin1ΔPV mice, MK-801 induced medial-prefrontal delta (4 Hz) oscillations, and
impaired performance on tests of motor coordination, working memory and sucrose preference, even at lower doses than in wild-
type controls. We also found that untreated Grin1ΔPV mice are largely normal across a wide range of cognitive functions, including
attention, cognitive ﬂexibility and various forms of short-term memory. Taken together these results argue against PV-speciﬁc
NMDAR hypofunction as a key starting point of schizophrenia pathophysiology, but support a model where NMDAR hypofunction
in multiple cell types contribute to the disease.
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INTRODUCTION
Schizophrenia is a common and debilitating disease with a wide
spectrum of symptoms. While positive symptoms such as
hallucinations and delusions are central to its diagnosis, a large
share of the disease burden results from negative and cognitive
symptoms, such as social withdrawal, decreased motivation, and
anhedonia, or deﬁcits in working memory, attention and cognitive
ﬂexibility, respectively.1 Positive symptoms are related to exces-
sive dopaminergic signaling and can be moderated accordingly
by dopamine receptor antagonists. Negative and cognitive
symptoms, however, do not reliably respond to neuroleptic
treatment, and correlate with poor outcome.2
The observation that acute pharmacological blockade of NMDA-
type glutamate receptors (NMDARs) induces positive, as well as
cognitive and negative symptoms of schizophrenia in healthy
individuals3,4 has put NMDAR hypofunction at the center of much
current thinking on schizophrenia pathogenesis, primary to
dopaminergic hyperfunction.5,6 The counter-intuitive ﬁnding that
blockade of excitatory NMDARs, by a low dose of antagonist,
induces an increase in local neural activity has led to the
hypothesis that it is NMDARs on inhibitory interneurons that are
preferentially affected by NMDAR blockers, causing a net
disinhibition of principal cell activity.5,7–9 Furthermore, post-
mortem ﬁndings have implicated interneurons positive for
parvalbumin (PV) in the disease process.10,11 Consequently, the
hypothesis that NMDAR hypofunction on PV interneurons is at the
core of the pathophysiology of schizophrenia has been advanced
in multiple versions.6,12–14 A dominant model is that the resulting
net disinhibition of principal cell activity increases the excitatory
output of the ventral hippocampus, which could then lead to a
dopaminergic hyperfunction, via polysynaptic loops through the
basal ganglia.6
To test this PV-interneuron-NMDAR hypofunction hypothesis,
several laboratories have generated genetically modiﬁed mice
with conditional knockout of the obligatory GluN1 subunit of the
NMDA-receptor in PV interneurons, although with varying degrees
of speciﬁcity (Grin1ΔPV).15–18 The behavioral phenotypes of these
mice, on tests that might be considered relevant to schizophrenia,
however, are highly variable across studies, and in many cases
indistinguishable from controls.17–20 Nevertheless, two studies
have reported that NMDAR deletion in PV interneurons prevents
the hyperlocomotion-inducing actions of the non-competitive
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NMDAR antagonist, MK-801.15,17 The induction of hyperlocomo-
tion by MK-801 (as well as by pro-dopaminergic drugs such as
amphetamine) represents the most widely used animal model of
positive symptoms of schizophrenia. This gains face validity from
the observation that these drugs induce psychosis in healthy
humans, and that both positive symptoms in patients and drug-
induced hyperlocomotion in mouse models are attenuated by
neuroleptic drugs. The absence of MK-801-induced hyperlocomo-
tion in Grin1ΔPV mice supports the hypothesis that NMDAR
antagonists produce their psychotic effect speciﬁcally by blocking
NMDARs on PV interneurons, and by extension constitutes some
of the strongest evidence in favor of the PV-interneuron-NMDAR
hypofunction hypothesis of schizophrenia.
However, this conclusion requires further scrutiny for several
reasons: ﬁrst, if it is speciﬁcally the blockade of NMDARs on PV
interneurons that induces hyperlocomotion and other
schizophrenia-relevant phenotypes, then why does knockout of
NMDARs in such neurons not cause reliable cognitive deﬁcits and
hyperlocomotion in the ﬁrst place?15,17,18,20 Second, locomotor
activity is a rather non-speciﬁc assay of behavior and its
automated analysis via infrared beam-break counts may be
affected by sedation and various other behaviors such as
stereotypies. Third, studies of genetically modiﬁed mice in which
NMDARs have been selectively ablated from principal cells in the
forebrain have revealed robust hyperactivity, as well as deﬁcits in
tests of cognition that might be relevant to schizophrenia.21–29
Taken together, these observations call for closer scrutiny of the
evidence that NMDARs solely on interneurons mediate the
behavioral effects of NMDAR blockade.
We therefore undertook a detailed re-analysis of schizophrenia-
related behavioral phenotypes in Grin1ΔPV mice. We also re-
examined the effects of MK-801 on locomotor activity in these
animals, as well as on other phenotypes associated with the drug.
We show that untreated Grin1ΔPV mice are largely normal across a
wide range of schizophrenia-related behavioral tests. Furthermore,
we show that rather than being protected against the effects of
MK-801 Grin1ΔPV mice are in fact sensitized to its actions.
MATERIALS AND METHODS
Subjects
To achieve NMDAR ablation speciﬁcally in PV interneurons, we crossed a
widely used and validated PV-Cre-driver line30 with the Grin1-2lox line used
in the study that showed, as far as can be compared, the strongest
behavioral deﬁcits overall.16 This Grin1-2lox line features a smaller distance
(3.3 kB) between the loxP sites compared with other lines used for
conditional Grin1 knockout,25 and is therefore expected to lead to NMDAR
ablation earlier in development and hence stronger phenotypes.15 Mice
harboring one copy of Cre and two copies of the Grin1-2lox allele were
used as PV-interneuron-speciﬁc knockouts (hereafter Grin1ΔPV or knock-
outs). Littermates with no copy of Cre, but one (Grin1loxP/+) or two
(Grin1loxP/loxP) copies of the Grin1-2lox allele (hereafter Grin1-2lox or
controls) were used as the control group. We conﬁrmed, that the PV-Cre
driver line we used achieves near-complete coverage of the neocortical PV-
cell population (96% on average) and very comprehensive targeting of the
hippocampal PV-neurons (84%) by 2 months of age, producing a
signiﬁcantly reduced NMDAR-current in PV-cells of knockouts (see
Supplementary Figure S1), in agreement with previous data.17 Hence,
mice were tested from the age of 2 months onwards to ensure NMDAR
hypofunction across the PV-cell population.
Behavioral assessment of Grin1ΔPV mice
To investigate the causal involvement of NMDAR hypofunction, speciﬁcally
in PV-cells, in schizophrenia-related behavioral phenotypes, we used two
complementary approaches: ﬁrst, we performed an extensive behavioral
assessment of Grin1ΔPV mice, and second we tested the impairments
induced by pharmacological NMDAR blockade with MK-801 in control and
Grin1ΔPV mice.
Male and female Grin1ΔPV mice and their littermate controls were
assessed on a battery of behavioral tests related to schizophrenia. This
included novelty-induced hyperlocomotion, pre-pulse inhibition (PPI) and
habituation of startle response, spatial working memory (rewarded
alternation) in the T-maze, spontaneous spatial novelty preference in the
Y-maze, novel-object recognition, social memory, reversal learning in the
plus maze, the ﬁve-choice serial reaction time task (5-CSRTT) and sucrose
preference. Tests of anxiety—the elevated plus maze, light–dark box and
hyponeophagia—were also conducted. Detailed methods for each test are
provided in Supplementary Materials and Methods.
The effects of MK-801 in Grin1ΔPV mice
In addition, we also assessed the effects of the NMDAR antagonist MK-801
(dizocilpine maleate) on behavioral performance and in vivo electrophy-
siology in Grin1ΔPV mice and controls. Mice were injected i.p. with MK-801
(dose range 0.1–0.5 mg kg− 1) or saline vehicle prior to assessment of
locomotor activity in photocell activity cages. Behavioral scoring was also
used to quantify the presence of stereotypy, catalepsy and ataxia during
assessment of locomotor activity (see Results). We also investigated the
effects of MK-801 or vehicle injection in Grin1ΔPV mice and controls on the
accelerating rotarod test of motor coordination, spatial working memory
(rewarded alternation on the elevated T-maze), a sucrose preference test of
anhedonia and during in vivo recording of local ﬁeld potentials in mPFC
(see Supplementary Materials and Methods for full details).
RESULTS
Behavioral assessment of Grin1ΔPV mice
NMDAR hypofunction in hippocampal PV interneurons has been
proposed to disinhibit hippocampal principal cell output and
consequently induce over-activity of downstream dopaminergic
neurons, causing both enhanced locomotor activity and reduced
PPI.6 Previous studies have, however, failed to ﬁnd such predicted
phenotypes in Grin1ΔPV mice.15,17,20 We re-examined locomotor
activity in two cohorts, at different ages. We observed a
signiﬁcantly increased locomotion in knockouts at around
5 months (P= 0.001) but not around 2 months of age (P= 0.78;
age–genotype interaction: P= 0.02, analysis of variance (ANOVA);
Figures 1a and b; see Supplementary Table S1 for statistical details
on this and all subsequent tests). We next tested inhibition of
startle responses at four pre-pulse intensity levels and found no
evidence of a PPI deﬁcit (P= 0.46, effect of genotype, Figure 1c),
nor abnormal habituation of the startle response across the
session (P= 0.527, genotype–phase interaction, repeated mea-
sures ANOVAs; Figure 1d, 5 months of age).
Schizophrenia may entail ﬂattening of affect, including a
decreased sense of pleasure (anhedonia) and an increased co-
morbidity with anxiety disorders.31 Using the preference for a
rewarding stimulus (10% sucrose solution) as a measure of
hedonic motivation we found no effect of genotype (P = 0.963,
ANOVA; Figure 1e), in line with previous evidence.32 Uncondi-
tioned anxiety, in contrast to expectation, was mildly decreased in
young knockouts when measured in the elevated plus maze but
appeared largely normal in two other tests (Supplementary
Figure S2).
Previous studies have reported impairments in Grin1ΔPV knock-
out mice on cognitive tasks, such as working/short-term
memory,15–17 although others have failed to detect such
deﬁcits.18,20 We therefore assessed our Grin1ΔPV mice in a battery
of cognitive tests. We ﬁrst assessed short-term memory for objects
(novel-object recognition), and for spatial (spatial novelty pre-
ference, Y-maze) and social (three-chamber social memory
paradigm) stimuli. Grin1ΔPV mice showed a robust preference for
the novel stimulus in all paradigms, indicating a memory for the
familiar stimulus encountered during the sample trial (Po0.05,
one-sample t-test against chance level of 0.5), and did not differ
signiﬁcantly from controls (P40.2, ANOVA; Figure 1f,
Supplementary Table S1).
Likewise, in the T-maze test of spatial working memory,
knockouts performed well above chance levels in all blocks of
testing (Po0.0005; one-sample t-test against 0.5; Figure 1g).
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Figure 1. Schizophrenia-related endophenotypes and cognitive function in Grin1ΔPV mice. (a and b) Novelty-induced hyperlocomotion: (a)
Average beam-break counts over 2 h aggregated in 5-min bins for cohorts of 2 months (left) and 5 months (right) age (Error bars: s.e.m.). (b)
Average total beam breaks for both age groups as indicated. Different age groups are distinct cohorts. (c) Average pre-pulse inhibition
expressed as % for the individual dB-levels of pre-pulse. (d) Average absolute response to the startle-pulse (120 dB) at start and end of the test
sequence, showing habituation to the startle-pulse over time. (e) Sucrose preference for 3 consecutive days during which two water bottles
were presented in the ﬁrst day, and one water and one bottle with 10% sucrose solution was offered on 2 consecutive days. Line graphs (left
axis) represent the preference for the bottle that contained sucrose on days 2–3, while bar graphs show the absolute consumption of water
(light blue/red) and sucrose (dark blue/red; right axis). (f) Short-term memory for spatial, non-spatial or social stimuli as indicated, assessed by
spatial novelty preference (Y-maze), novel-object recognition and the three-chamber social memory task, respectively. Preference scores were
calculated as the total time spent with the novel stimulus divided by the time spent with both stimuli combined. The yellow line indicates
equal preference (chance levels). (g) Spatial working memory: correct choices (alternation of choice arm from sample to choice run) in the
rewarded alternation paradigm in the T-maze are shown for training days 1–3 with 5-s intra-trial interval (ITI), and test days with 1 s and 15 s
ITI. ITI-numbers are written in black to indicate round-robin and gray for massed trails. The same cohort was trained and tested twice at
2 months (left) and 6 months (right) of age. The yellow line indicates chance level. (h and i) Spatial reference memory and cognitive ﬂexibility:
(h) Percent of correct choices in the previous 20 trials in the plus maze plotted in intervals of 5 trials during acquisition and reversal learning.
(i) Average number of blocks needed to reach criterion (85% correct in the previous 20 trials). (j–n) Averaged measures from the ﬁrst 2 sessions
in each of the 6 training stages mice were taken through in the 5-CSRTT (see Supplementary Methods for details): (j) % accuracy, (k) % correct
responses, (l) % perseverative responses, (m) % premature responses and (n) reward latency. Blue, controls; red, knockouts. Asterisks indicate
signiﬁcant differences at Po0.05 measured by the appropriate statistical test (see Supplementary Table S1 for details). Error bars indicate 95%
conﬁdence intervals except were indicated otherwise. Ctrl, control; KO, knockout.
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Across the three different protocols tested (see Figure 1g), there
was no signiﬁcant main effect of genotype at either 2 (P = 0.393) or
6 (P = 0.232) months of age (repeated measures ANOVA). A
previous study reported a working memory deﬁcit when switching
to a very short intra-trial interval of 1 s applied in massed trials.17
We therefore reproduced such a protocol-switch on the fourth day
at both ages (2 and 6 months), and indeed found a signiﬁcantly
decreased performance in knockouts (P= 0.004, repeated mea-
sures ANOVA across both ages). This effect of genotype, however,
did not reach statistical signiﬁcance at 6 months of age alone
(P= 0.084, t-test), which prompted us to repeat that 1-s protocol
on day 6 of that training phase at 6 months. Grin1ΔPV and control
mice performed equally during that repetition (P= 0.959, t-test;
Figure 1g). Therefore, this subtle and transient decrease in spatial
working memory performance is unlikely to reﬂect a robust
impairment of working memory processes, but may instead reﬂect
increased sensitivity to a change in testing protocols.
Impaired cognitive ﬂexibility and attention, as well as increased
perseveration are often considered hallmarks of schizophrenia. We
used reversal learning in an appetitively motivated, discrete-trial,
spatial choice task in an enclosed plus maze to measure cognitive
ﬂexibility. In line with a previous study which assessed spatial
learning in the water maze,17 neither acquisition nor reversal of
this associative memory were impaired (P40.6, t-tests for number
of trials to reach criterion; P40.8 for main effects of genotype
across blocks, repeated measures ANOVAs; Figures 1h and i).
We also assessed performance on the 5-CSRTT, which is
considered analogous to the continuous performance test that
is often used to assess attentional performance in patients with
schizophrenia.33 We trained mice through six stages during which
the duration of the visual stimulus was gradually reduced to 1 s.
There was no effect of genotype on measures of attention (%
accuracy, % correct), perseveration (% repeated correct responses)
or impulsivity (% premature responses; Figures 1j–m; see
Supplementary Table S1 for statistics).33 Grin1ΔPV mice were,
however, faster to collect rewards during the task, which could
reﬂect increased locomotor activity or increased motivation
(Figure 1n).
In summary, despite the fact that our test battery covers a large
—though not complete—range of schizophrenia-related deﬁcits,
Grin1ΔPV mice displayed a surprising lack of behavioral aberrations,
except for a mild hyperactivity at 5 months of age. It is imaginable
that such a lack might—at least in part—be due to some
compensation of NMDAR hypofunction by increasing expression
of other excitatory channels over time. Therefore, we next
conducted a complementary analysis of the involvement of PV-
NMDARs in schizophrenia-related deﬁcits assessing the effects of
the non-competitive NMDAR antagonist, MK-801, in knockout
mice and controls: If the lack of phenotype is due to compensa-
tion, while the hypothesis that the induction of schizophrenia-
related deﬁcits by MK-801 is largely mediated by action of the
drug on PV-NMDARs holds (see Introduction), our knockouts
should be protected against its effect.
Grin1ΔPV mice are not protected from the effects of MK-801 on
locomotor activity
Two pioneering studies on interneuron-speciﬁc NMDAR-knockout
mice reported that MK-801 fails to induce hyperlocomotion
normally observed in wild-type mice.15,17 We re-examined this
issue (see Introduction) by combining locomotor activity monitor-
ing with detailed, on-line behavioral scoring and tested three
doses of MK-801 (0.1, 0.2 and 0.5 mg kg− 1).
In wild-type mice, MK-801 produced a dose-dependent increase
in spontaneous locomotion as expected (Figure 2a). We classiﬁed
other MK-801-induced motor aberrations into three types: (1)
stereotypies, mainly consisting of circling but also repetitive
head-shaking, face-washing, grooming or jumping; (2) ataxia or
'tumbling' characterized by repeated loss of balance while walking
or rearing (Supplementary Video 1); and (3) catalepsy, correspond-
ing to extended periods lasting up to several minutes of complete
immobility. From ~15 min post injection onwards, such episodes
of immobility were distinguishable from periods of normal rest or
sleep in vehicle-injected animals because mice lacked the typical
rounded posture standing on four legs seen in control mice, and
instead exhibited a more stretched posture with the head and/or
body lying directly on the ﬂoor, and with legs stretched out
(Figure 2b; Supplementary Videos 2-4).
We ﬁrst conﬁrmed previous reports15,17 that in Grin1ΔPV mice
MK-801 almost completely failed to increase locomotion when
measuring aggregate beam-break counts over 60 min post
injection (drug–genotype interactions for MK-801 doses in
mg kg− 1: 0.1: P= 0.023, 0.2: P = 0.001, 0.5: Po0.0005; effects of
drug: 0.1: P= 0.801, 0.2 and 0.5: Po0.0005, ANOVA; Figures 2c–e;
see Supplementary Table S2 for details on this and all subsequent
statistics). At none of the doses tested did MK-801 signiﬁcantly
increase the total beam-break counts over the ﬁrst 60 min in
knockouts relative to vehicle (P40.2 for 0.2 and 0.5 mg kg− 1;
P= 0.074 for 0.1 mg kg− 1 with MK-injected knockouts displaying
lower beam breaks, ANOVA; Figures 2c–e). In contrast, in controls
total locomotor activity was profoundly increased by MK-801 at
the two higher doses (Po0.0005, ANOVA) relative to vehicle.
However, closer inspection of the animals’ behavior demands a
re-interpretation of this observation. First, when measuring
aggregate beam-break counts over the last 30 min only (60–
90 min post injection), MK-801 actually induced signiﬁcant
hyperlocomotion in knockouts (Po0.005 for effects of 0.2 and
0.5 mg kg− 1 MK-801 within knockout group, ANOVA), albeit less
than in control mice (Po0.02 for effects of genotype within
MK-801-injected mice; Po0.01 for drug–genotype interaction,
ANOVAs; Figure 2i, see also Figures 2f–h and ref. 15).
Second, manual scoring revealed that the lower beam-break
counts in MK-801-injected Grin1ΔPV mice were mainly accounted
for by extended periods of catalepsy (Figures 2j–l). At higher doses
(0.2 and 0.5 mg kg− 1) catalepsy was observed in every knockout
mouse, but was virtually absent in wild-type mice (Po0.0005,
Mann–Whitney (MW) U-test; Figures 2j–l). During blind-to-
genotype observations, only 2 out of 24 wild-type mice exhibited
a single episode each classed as cataleptic. Indeed, the genotype
could be predicted virtually without error from this recurring
MK-801-induced trait.
Third, knockout mice spent more time engaged in stereotypies
at 0.2 mg kg− 1 compared with MK-801-injected controls
(P= 0.016, MW U-test, Figures 2j and m). Interestingly, however,
knockouts displayed very little MK-801-related disturbance of
balance (ataxia) in the locomotor activity cages, while all controls
were affected (0.2 mg kg− 1: P= 0.016, 0.5 mg kg− 1: Po0.0005;
MW U-tests, Figures 2j, k and n).
We next tested whether the reduced locomotor activity in
Grin1ΔPV mice following MK-801 could indicate a general lack of
sensitivity to psychostimulants by assessing the locomotor
response to amphetamine, a drug that directly increases
dopaminergic signaling. However, knockouts were at least as
responsive to its locomotor activity-inducing effect as controls
(effect of drug: Po0.0005, drug–genotype interaction: P= 0.41,
ANOVA; Figure 2o).
Grin1ΔPV mice are sensitized to MK-801-induced impairments of
coordination and cognition
These results suggest that NMDAR blockade may still induce some
hyperlocomotion and stereotypy, that is, potential correlates of
psychosis and habitual behavior, in Grin1ΔPV knockout mice, and
that following MK-801 injection beam-break counts in knockouts
are only lower than in controls because of drug-induced catalepsy
in the former. To test this interpretation further, we assessed
PV-NMDAR hypofunction sensitizes to MK-801
AM Bygrave et al
4
Translational Psychiatry (2016), 1 – 9
motor performance on the accelerating rotarod in both genotypes
at an intermediate dose of the drug (0.15 mg kg− 1 in females,
0.2 mg kg− 1 in males). If knockouts are really protected from
motor effects of NMDAR blockade as suggested,15,17 then they
should perform at least as well on the rotarod as MK-801-injected
controls.
In both males and females, the time on the accelerating rotarod
was signiﬁcantly lower for MK-801-injected knockout mice
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Figure 2. Effect of MK-801 on locomotor activity. (a) Dose–response curve of total beam breaks in 90 min post injection for rising doses of
MK-801 (0.025 to 0.4 mg kg− 1, n= 4 per dose) in male C57bl6 mice. (b) Knockout mouse in MK-801-induced catalepsy (see also
Supplementary Videos 2-4). (c–e) Total beam breaks for 60 min post injection for 0.1 (c), 0.2 (d) and 0.5 (e) mg kg− 1 MK-801 vs vehicle.
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males; open circles, females. Asterisks indicate signiﬁcant pair-wise differences (Po0.05, MW U-test or t-test as appropriate). (l–n) % time spent
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MK-801. (o) Total beam-break counts over 90 min after injection of 0.2 mg kg− 1 amphetamine (dark blue, dark red) or vehicle (light blue, light
red). Asterisks indicate signiﬁcant differences between drug-injected groups and relevant control groups (Po0.05, ANOVA). Error bars
represent s.e.m. in line graphs (f–h) and otherwise 95% conﬁdence intervals. All experiments were conducted as between-subjects designs.
MK-801 (dark blue, dark red) or vehicle (light blue, light red) indicated in control (blue) and knockout (red) mice. Gray numbers represent
doses of MK-801 for each panel. ANOVA, analysis of variance; Ctrl, control; KO, knockout; NS, not signiﬁcant.
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compared with MK-801-injected controls, as well as compared
with vehicle-injected knockouts (Po0.01, t-tests; drug–genotype
interaction: Po0.01, ANOVA; 60 min post injection; Figures 3a–c).
The number of failures, that is, occasions of falling off the rotarod
before acceleration even started, was signiﬁcantly higher in
MK-801-injected knockouts than in both MK-801-injected controls
and vehicle-injected knockouts (Po0.05, 60 min post injection,
MW U-test; Figure 3c). The rotarod test thus provides further
evidence that Grin1ΔPV mice are more sensitive to MK-801-
mediated motor disturbances than controls.
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Acute administration of NMDAR antagonists not only induces
locomotor effects but also impairments in cognition,34–37 includ-
ing in spatial working memory on the T-maze.38 We trained a
cohort of Grin1ΔPV mice and controls on the rewarded alternation
T-maze paradigm, which we had used previously (Figure 1g). After
training each animal to criterion, we assessed mice at doses
of 0.1, 0.15, 0.2 and 0.4 mg kg− 1 MK-801, starting at 30 min post
injection. For each individual dose, we included a separate within-
subjects vehicle control condition (fully counterbalanced). We
found an MK-801-induced impairment for both genotypes only at
a dose of 0.4 mg kg− 1 (main effect of drug at 0.4 mg kg− 1:
Po0.0005; P40.1 at other doses; drug–genotype interaction at
0.4 mg kg− 1: P= 0.336; repeated measures ANOVA, Figure 3d). At
the lowest dose (0.1 mg kg− 1) in turn there was no signiﬁcant
impairment (P40.1 for effects of drug, genotype and drug–
genotype interaction, repeated measures ANOVA). At intermedi-
ate doses (0.15 and 0.2 mg kg− 1), however, Grin1ΔPV knockouts
were already signiﬁcantly impaired compared with vehicle
condition (Po0.05, paired samples t-tests) while controls were
not (drug–genotype interaction: Po0.02, repeated measures
ANOVA for both drug doses separately; Figure 3d). There was no
overall effect of genotype during the training phase or on vehicle
days, indicating equivalent baseline performance of knockouts
and controls (P40.5, repeated measures ANOVAs), consistent with
our earlier observations (Figure 1g). Thus, Grin1ΔPV mice were
sensitized to the amnestic effects of MK-801. Importantly, we did
not observe catalepsy or any other gross motoric impairment
during spatial working memory testing with the drug in either
genotype in food-deprived mice that would have resulted in a
failure to travel swiftly through the maze to the food wells: choice
latencies remained largely in the normal range (under 10 s), even
at the highest dose of MK-801 in the knockouts (Figure 3e).
Finally, to assess the generality of this ﬁnding, we also examined
the reduction in sucrose preference seen with MK-801, which
might relate to the anhedonia-like aspect of negative symptoms
seen in some patients with schizophrenia.39 We tested the
preference for 1% sucrose solution after treatment with 0.1 and
0.15 mg kg− 1 MK-801 during a 2.5 h post injection period. We
found that at the lower dose of the drug (0.1 mg kg− 1), only
knockouts showed a signiﬁcant decrease in sucrose preference
(drug–genotype interaction: P= 0.012; no effect of drug: P= 0.965
or genotype: P = 0.960, repeated measures ANOVA). In contrast, at
the higher dose of MK-801, there was reduced sucrose preference
in both genotypes (no drug–genotype interaction: P= 0.276;
signiﬁcant main effect of drug: P = 0.026, but not of genotype:
P= 0.798; repeated measures ANOVA; Figure 3f).
MK-801 induces cortical delta-oscillations in Grin1ΔPV mice
The decrease of working memory already at intermediate doses of
MK-801 in knockouts speaks to a perturbation of prefrontal or
hippocampal circuits. To assess this further, we recorded local ﬁeld
potentials in medial-prefrontal cortex and CA1-hippocampus
10 min before and 20–30 min after injection of 0.2 mg kg− 1
MK-801 or vehicle in freely moving mice. While local ﬁeld
potentials in control mice did not display apparent MK-801-
induced changes in either of those areas, prefrontal cortex in
Grin1ΔPV mice became dominated by slow oscillations (Figure 4a).
Power-spectral analysis conﬁrmed the emergence of a peak at
~ 4 Hz (Figure 4b). The total relative power in the high delta range
(3–5 Hz) increased signiﬁcantly in Grin1ΔPV mice treated with
MK-801 compared with MK-801-injected controls (P= 0.03 t-test),
as well as compared with the vehicle condition (drug–genotype
interaction: P= 0.019, repeated measures ANOVA; Figure 4c). It is
imaginable that engagement of prefrontal network activity by
such dominant oscillations, which normally occur only during
non-REM sleep,40 interferes with working memory processes.
DISCUSSION
Grin1ΔPV knockout mice do not display marked cognitive
impairments
In the present study we have shown that, under baseline
conditions, Grin1ΔPV mice exhibit mild, age-dependent locomotor
hyperactivity, but otherwise little, if any, aberrant phenotype
across a wide battery of cognitive tasks that might be considered
relevant to schizophrenia, including measures of working or short-
term memory, attention, PPI and cognitive ﬂexibility. This cannot
be explained by ineffectiveness of knockout as we combined a
PV-Cre driver with comparatively high coverage of the PV-cell
population (see Supplementary Figure S1) with a Grin1-2lox
responder line that features a short distance between loxP sites
(see Supplementary Table S3), which should facilitate NMDAR
knockout.15,16 Our data therefore question a circuit model in
which PV-speciﬁc NMDAR hypofunction is a causal starting point
of schizophrenia pathology.6 Failure to induce a robust phenotype
by deletion of NMDARs in PV interneurons largely agrees with
earlier studies using the same PV-Cre driver line (see Supple-
mentary Table S3), which repeatedly failed to detect profound
deﬁcits in working memory (using various T-maze tasks), cognitive
ﬂexibility (using reversal learning in the water maze) or PPI.17,18,20
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(right, red) mice before (top) and 27 min after (bottom) injection of
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power spectral density. Gray bar highlights the area of 3–5 Hz
containing the peak of the induced delta-oscillations and used for
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These results, however, stand in contrast with a study that used a
different driver line, which targets only a subset of the brain’s
PV interneurons, mainly located in the hippocampus,41,42 and
revealed an impairment of short-term memory.16
Grin1ΔPV knockout mice exhibit increased sensitivity to MK-801
Considering that the behavior of Grin1ΔPV mice was either normal
or showed subtle alterations under baseline conditions, their clear
divergence from wild-type behavior under MK-801-treatment is
striking. The experimental logic of such experiments is that
knockouts should be protected against MK-801-induced effects
assuming these effects are caused by blocking NMDARs on PV
interneurons in control mice.
Contrary to previous conclusions,15,17 however, we found that
Grin1ΔPV mice are not protected against most behavioral effects of
MK-801 that we tested. Instead they were even sensitized to the
drug’s action in several paradigms: knockouts displayed increased
stereotypies, as well as strong catalepsy compared with drug-
treated control mice. Moreover, MK-801 induced deﬁcits in motor
coordination, spatial working memory and sucrose preference at
lower doses in Grin1ΔPV mice than in controls indicating their
sensitization to the drug. Even mild hyperlocomotion, a mouse
correlate of psychosis, was evident with MK-801 in Grin1ΔPV mice
after 1 h post injection when episodes of catalepsy became less
pronounced. Thus, NMDARs on PV interneurons are not the
(primary) site of drug action for these behavioral effects of non-
competitive NMDAR antagonists, and, by inference, the virtual lack
of a phenotype in baseline behavior cannot simply be explained
by compensatory mechanisms.
Implications for neural circuit models of schizophrenia
In summary, our data argue against the hypothesis that NMDAR
hypofunction speciﬁcally on PV interneurons is central to the
psychotic and cognitive symptoms of schizophrenia. Instead, PV-
NMDAR hypofunction appears to predispose or sensitize the
circuit to some behavioral consequences of reduced NMDAR-
signaling in other neurons in the circuit. PV-NMDAR hypofunction
may thus be one of many potential risk factors of the disorder.
The ﬁnding that some deﬁcits are provoked by long-term social
isolation stress in one interneuron-speciﬁc NMDAR-knockout
line,15,19 as well as by ageing as described here for hyperlocomo-
tion, supports this risk-factor-model. Also, our conclusion is
arguably more consistent with the data in schizophrenia itself:43
although several pathological studies have reported a reduced
expression of NMDAR subunits, including in interneurons44,45
there is little evidence that interneurons, let alone the PV subclass,
are disproportionately affected.46 Further in line with our results,
several other studies have found that targeting NMDAR knockout
exclusively to speciﬁc excitatory cells of the forebrain may cause
profound schizophrenia-related deﬁcits, including impairments of
short-term or working memory, sociability and PPI, as well as
increased hyperlocomotion.25,26,29,47
Instead a more complex framework, which can accommodate
NMDAR hypofunction at more than one node in the network and
can explain the interaction between these nodes, is necessary. At
this stage one can only speculate about the nature of such an
interaction. One possibility is, that NMDARs expressed by multiple
cell types in cortical circuits collectively help to ﬁne-tune the
balance between excitation and inhibition (E/I balance): From this
perspective, an NMDAR blockade in Grin1ΔPV mice would equate
to a depression of cortical network activity because excitatory
drive is removed predominantly from excitatory cells, not from PV
interneurons. Such depression, if occurring in motor-related areas,
might be the cause of the catalepsy we observed. In wild-type
mice, in contrast, excitatory drive is removed from inhibitory
PV-neurons as well, thereby preventing such depression. A related
possibility is the induction of an imbalance between cortical and
thalamic circuits: delta-oscillations, which normally occur only
during slow-wave sleep, can also be observed during the awake
state in the ventromedial prefrontal cortex in patients with
schizophrenia.48 It has been suggested, that these oscillations
result from a hypofunction of NR2C-containing NMDARs in the
thalamus, potentially in PV interneurons enriched in this region.49
This speciﬁcation of the hypothesis is disproved by the fact that
we could induce strong prefrontal delta-oscillations with MK-801
in mice in which NMDARs on PV-cells are missing. However, our
data leave open the possibility that NMDAR blockade on other
thalamic cell types causes a cortico-thalamic imbalance. A further
possible correlate of the sensitization to impairment of motor
coordination is an alteration of cerebellar circuits, which also
contain PV interneurons. Besides, the schizophrenia-related role of
the minority of excitatory PV-positive cells in the brain50 remains
to be elucidated. Our approach demonstrates the utility of cell
type-speciﬁc NMDAR-knockout mice as experimental tools for
mechanistic investigation of the glutamate hypothesis of schizo-
phrenia, even if such mice cannot be considered models of this
disease.
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